INSULINOMA MISDIAGNOSED AS NEUROLOGIC DISEASE

J. Salavessa¹, V. Gomes², F. Ferreira³, C. Alcântara¹

1 – Internal Medicine Department, Hospital de Santa Maria, CHLN – EPE, Lisbon, Portugal
2 – Endocrinology, Diabetes and Metabolism Department, Hospital de Santa Maria, CHLN – EPE Lisbon, Portugal

INTRODUCTION

Insulinoma is a rare pancreatic endocrine tumour derived from β cells that secrete insulin. Most are benign and solitary.¹ The median age at diagnosis is about 47 years and it is more prevalent in women.¹,² The common clinical manifestation of insulinoma is Whipple’s triad which consists of hypoglycemia, associated neuroglycopenic and sympathoadrenal symptoms and resolution of the clinical signs with the administration of glucose.³ Diagnosis relies on clinical features along with laboratory tests and imaging. However, the nonspecific symptoms and small size of these tumours can lead to difficulties of diagnosis and localization.¹

CASE REPORT

CLINICAL PRESENTATION

• 84 year old male, admitted to the emergency department of a central Hospital in Lisbon (Portugal), with seizures.
• Previous history of fatigue, dizziness and tremors for the past two years, diagnosed as Parkinson’s disease.
• Physical examination: Glasgow Coma Scale 13 (E 3; V 4; M 6), confusion, abnormal behaviour and severe hypoglycemia (44 mg/dL).
• The symptoms resolved after intravenous glucose administration.

LABORATORY TESTS

• 72 hour fast test showed increased levels of insulin, C-peptide and pro-insulin, consistent with endogenous hyperinsulinism. (table 1).
• Screening for sulfonylurea, anti-insulin antibodies and anti-insulin receptor antibodies was negative.
• MEN 1 syndrome was excluded.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Patient</th>
<th>Endogenous Hyperinsulinism criteria ²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucose</td>
<td>38 mg/dL</td>
<td>≤ 45 mg/dL</td>
</tr>
<tr>
<td>Pro-insulin</td>
<td>51,7 pmol/L</td>
<td>≥ 5 pmol/L</td>
</tr>
<tr>
<td>Insulin</td>
<td>7,1 mU/L</td>
<td>≥ 3 mU/L</td>
</tr>
<tr>
<td>C-peptide</td>
<td>2,21 ng/mL</td>
<td>≥ 0,6 ng/mL</td>
</tr>
</tbody>
</table>

Table 1: 72 hour fast test

IMAGIOLOGY

• Abdominal computed tomography (CT) scan: revealed a 12,1 mm hypervascular nodule in the uncinate process of the pancreas (figure 1).

![Figure 1: abdominal CT scan](image)

• Endoscopic ultrasonography and biopsy: showed a hypoechoic nodule with 12x7 mm in the uncinate process of the pancreas. The histopathology was suggestive of a neuroendocrine tumour.

TREATMENT

• Medical therapy: Diazoxide (200 mg/day) and poli-fractionated diet until surgery.
• Surgery: enucleation of the pancreatic tumour. The histopathology was consistent with the diagnosis of benign insulinoma.

The clinical course was favourable, with regression of symptoms and blood glucose normalization, without medical therapy.

CONCLUSION

Insulinoma remains a diagnostic challenge since symptoms are nonspecific and may lead to incorrect diagnosis. As in this clinical case, a neurologic disease might be considered the culprit. Retrospectively, the patient’s symptoms (fatigue, dizziness and tremors) can be interpreted as hypoglycemic episodes caused by the insulinoma. It is important to consider this diagnosis, because severe and sustained hypoglycemia can lead to disability and death. On the other hand, it is easily confirmed by standard endocrine tests and insulinoma can be potentially curable through surgical resection.

References:
2-Hypoglycemia in persons without diabetes. Dynamed, Updated 2015 Feb 23
3-Zanera Ashraf A. Insulinooma. Mediscape. 2015